Steve Usdin
Washington Editor at BioCentury
Co-Host at BioCentury This Week
Washington Editor, BioCentury. Author: Bureau of Spies & Engineering Communism.
Articles
-
2 days ago |
biocentury.com | Steve Usdin
ARTICLE | Politics, Policy & LawCBER Director Prasad says patients ‘deserve cures’ and FDA has an obligation to move fast — but personnel cuts could slow implementation of reforms By Steve Usdin, Washington Editor Eager to demonstrate tangible successes in speeding reviews of new medicines and clearing away outmoded regulatory barriers, FDA Commissioner Marty Makary and senior FDA leaders are prioritizing reforms to the regulatory framework for therapies to treat rare diseases.
-
4 days ago |
biocentury.com | Steve Usdin
ARTICLE | Politics, Policy & LawHHS Secretary Kennedy, DOGE officials relied on data they knew was flawed, suit states By Steve Usdin, Washington Editor Vid Desai was serving as FDA’s chief information officer on April 1 when he, along with about 10,000 other HHS employees, learned he’d been laid off. Like many others, the “reduction-in-force” notice Desai received was riddled with factual errors.
-
1 week ago |
biocentury.com | Steve Usdin
ARTICLE | Politics, Policy & LawWhite House demanding 85% across-the-board drug price cuts; biopharma industry hopes to avoid catastrophic policies via alternative concessions By Steve Usdin, Washington Editor Biopharma leaders view President Donald Trump’s push for “most favored nation” drug pricing as a serious, urgent threat.
-
1 month ago |
biocentury.com | Steve Usdin
ARTICLE | Politics, Policy & LawTrade associations and biopharma CEOs are mobilizing to oppose the drug pricing policy By Steve Usdin, Washington Editor Pharmaceutical industry executives and lobbyists are in “Defcon 1,” the highest state of alarm, over President Donald Trump’s push to include a “most favored nation” policy for Medicaid drug purchases in budget reconciliation legislation.
-
1 month ago |
zephyrnet.com | Steve Usdin
ARTICLE | Politics, Policy & LawBy Steve Usdin, Washington EditorBiopharma CEOs and lobbyists are confident that the budget reconciliation bill will include relief from the Inflation Reduction Act's so-called "pill penalty," but are scrambling to fend off White House efforts to insert "most favored nation" drug pricing provisions. Even if MFN is excluded from the reconciliation bill, the push to ensure that some U.S. drug prices fall below those in other industrialized nations isn't going away.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 3K
- Tweets
- 4K
- DMs Open
- No
RT @BioCentury: Biopharma industry confident of IRA fix, hoping to dodge MFN, writes BioCentury's @SteveUsdin1 https://t.co/apTM0VaquL
RT @BioCentury: Three big disconnects: BioCentury's sentiment survey showed that biotech is still in shock. But behind the data, three deep…
FDA misses PDUFA goal for Stealth’s Barth syndrome treatment It isn’t clear whether staffing cuts or loss of FDA champions have caused FDA to miss the PDUFA goal for an ultrarare disease therapy. https://t.co/FnmhghTrgn